On May 23, 2006, the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, was launched to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.